论文部分内容阅读
目的探讨小牛血清去蛋白注射液联合自体骨髓干细胞(BMSCs)动员治疗重型颅脑损伤的临床疗效和安全性。方法选取60例重型颅脑损伤患者按随机数字表对照组(30例)和观察组(30例,在对照组治疗基础上加用小牛血清去蛋白注射液联合BMSCs动员治疗),比较两组患者间格拉斯哥评分(GCS)、神经功能缺损评分(NIHSS)及临床不良反应。结果两组患者伤后治疗14d、28d的GCS评分均较治疗前明显提高(P<0.05),并且观察组较对照组提高更为显著(P<0.05),而两组患者NIHSS评分均较治疗前明显降低(P<0.05),并且观察组较对照组降低更为显著(P<0.05);观察组外周血CD34+CD133+占外周血单核细胞比率治疗3w时明显高于对照组(P<0.05)。两组患者均未出现明显不良反应。结论小牛血清去蛋白注射液联合自体BMSCs动员可安全有效的促进重型颅脑损伤患者神经损伤修复,显著改善患者神经功能。
Objective To investigate the clinical efficacy and safety of bovine serum deproteinized injection combined with autologous bone marrow stem cells (BMSCs) mobilization in the treatment of severe craniocerebral injury. Methods Sixty patients with severe craniocerebral injury were randomly divided into two groups according to random number table control group (30 cases) and observation group (30 cases). The control group was treated with bovine serum deproteinized injection combined with BMSCs mobilization. Glasgow score (GCS), neurological deficit score (NIHSS) and clinical adverse reactions among patients. Results The scores of GCS on the 14th day and the 28th day after injury in the two groups were significantly higher than those before treatment (P <0.05), and the scores in the observation group were significantly higher than those in the control group (P <0.05) (P <0.05), and the observation group decreased more significantly than the control group (P <0.05). The ratio of CD34 + CD133 + peripheral blood mononuclear cells in the observation group was significantly higher than that in the control group at 3 weeks (P < 0.05). No significant adverse reactions occurred in both groups. Conclusion Bovine serum deproteinization combined with autologous BMSCs mobilization can safely and effectively promote the repair of nerve injury in patients with severe craniocerebral injury and significantly improve the neurological function.